Because drug-target MR proxies lifetime exposure to a pharmacological intervention, the results of this study should not be interpreted as evidence that the use of PDE5 inhibitors for current licensed indications is associated with Alzheimer’s disease. This evidence concerns the gene PDE5A and early-onset autosomal dominant Alzheimer disease.